Mayer-Davis EJ, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med. 2017;376(15):1419–29.

Article  PubMed  PubMed Central  Google Scholar 

Xie J, et al. Global burden of type 2 diabetes in adolescents and young adults, 1990–2019: systematic analysis of the Global Burden of Disease Study 2019. BMJ. 2022;379:E072385.

Article  PubMed  PubMed Central  Google Scholar 

Saeedi P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Prac. 2019;157:107843.

Article  Google Scholar 

Williams R, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108072.

Article  PubMed  Google Scholar 

Briggs AHD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15(6):835–42.

Article  PubMed  Google Scholar 

Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making. 2006;26(5):434–46.

Article  CAS  PubMed  Google Scholar 

Bojke LM, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health. 2009;12(5):739–49.

Article  PubMed  Google Scholar 

Frederix G, et al. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 2014;32(1):47–61.

Article  PubMed  Google Scholar 

Le QA. Structural uncertainty of Markov models for advanced breast cancer: a simulation study of lapatinib. Med Decis Making. 2016;36(5):629–40.

Article  PubMed  Google Scholar 

Silva-Illanes N, Espinoza M. Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening: a systematic review. Value Health. 2018;21(7):858–73.

Article  PubMed  Google Scholar 

Von Schéele B, et al. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):235–57.

Article  Google Scholar 

Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ. 2010;19(1):43–55.

PubMed  Google Scholar 

Palmer AJ, et al. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care. 2007;30(6):1638–46.

Article  Google Scholar 

Palmer AJBM. Computer modeling of diabetes and its complications: a report on the fifth mount hood challenge meeting. Value Health. 2013;16(4):670–85.

Article  PubMed  Google Scholar 

Tew M, et al. Exploring structural uncertainty and impact of health state utility values on lifetime outcomes in diabetes economic simulation models: findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. Med Decis Making. 2022;42(5):599–611.

Article  PubMed  Google Scholar 

Tarride J-E, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics. 2010;28(4):255–77.

Article  PubMed  Google Scholar 

Yi Y, et al. Economic models in type 2 diabetes. Curr Med Res Opin. 2010;26(9):2105–18.

Article  CAS  PubMed  Google Scholar 

Charokopou M, et al. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. Curr Med Res Opin. 2016;32(2):207–18.

Article  CAS  PubMed  Google Scholar 

Henriksson M, et al. A systematic review of cost-effectiveness models in type 1 diabetes mellitus. Pharmacoeconomics. 2016;34(6):569–85.

Article  PubMed  Google Scholar 

Li J, et al. Decision models in type 2 diabetes mellitus: a systematic review. Acta Diabetol. 2021;58(11):1451–69.

Article  PubMed  PubMed Central  Google Scholar 

Usman M, et al. Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: a systematic review and critical appraisal of decision-analytic models. Diabetes Res Clin Pract. 2020;161:108073–108073.

Article  PubMed  Google Scholar 

Asche CV, Hippler SE, Eurich DT. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics. 2014;32(1):15–27.

Article  PubMed  Google Scholar 

Ogurtsova K, et al. External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement-a protocol for a systematic review. Syst Rev. 2017;6(1):267–267.

Article  PubMed  PubMed Central  Google Scholar 

Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):B2535-b2535.

Article  PubMed  PubMed Central  Google Scholar 

Karagiannidou M, et al. Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer’s disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol. BMJ Open. 2018;8(6):E020638-e020638.

Article  PubMed  PubMed Central  Google Scholar 

Philips Z, et al. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006;24(4):355–71.

Article  PubMed  Google Scholar 

Caro JJMFF, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(6):796–803.

Article  PubMed  Google Scholar 

Palmer AJ, et al. Computer modeling of diabetes and its transparency: a report on the Eighth Mount Hood Challenge. Value Health. 2018;21(6):724–31.

Article  PubMed  PubMed Central  Google Scholar 

Popay J, et al. Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC Methods Progreamme. J Epidemiol Commut Health 2006;59(Suppl.1):A7.

Hayes AJ, et al. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925–33.

Article  CAS  PubMed  Google Scholar 

Lundqvist A, et al. Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS ONE. 2014;9(10):E110235-e110235.

Article  PubMed  PubMed Central  Google Scholar 

Viriato D, et al. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. J Med Econ. 2014;17(7):499–507.

Article  PubMed  Google Scholar 

Van der Heijden AAWA, et al. Policy evaluation in diabetes prevention and treatment using a population-based macro simulation model: the MICADO model. Diabet Med. 2015;32(12):1580–7.

Article  PubMed  Google Scholar 

Wolowacz S, et al. Development and validation of a cost-utility model for type 1 diabetes mellitus. Diabet Med. 2015;32(8):1023–35.

Article  CAS  PubMed  Google Scholar 

Ye W, et al. The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: development and validation. Diabetes Technol Ther. 2015;17(10):701–11.

Article  PubMed  PubMed Central  Google Scholar 

Valentine WJP, et al. The prime diabetes model: novel methods for estimating long-term clinical and cost outcomes in type 1 diabetes mellitus. Value Health. 2016;20(7):985–91.

Article  Google Scholar 

Willis M, Asseburg C, He J. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ. 2013;16(8):1007–21.

Article  PubMed  Google Scholar 

Willis M, et al. Validation of the economic and health outcomes model of type 2 diabetes mellitus (ECHO-T2DM). Pharmacoeconomics. 2017;35(3):375–96.

Article  PubMed  Google Scholar 

Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC Health Serv Res. 2018;18(1):78–78.

Article  PubMed  PubMed Central  Google Scholar 

Laiteerapong N, et al. Individualized glycemic control for U.S. Adults with type 2 diabetes a cost-effectiveness analysis. Ann Intern Med. 2018;168(3):170–8.

Article  PubMed  Google Scholar 

Nguyen E, et al. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complic. 2018;32(2):210–5.

Article  Google Scholar 

Shao H, et al. Novel risk engine for diabetes progression and mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). Pharmacoeconomics. 2018;36(9):1125–34.